# 04_QA_REPORT.md

# Quality Assurance Report

## Identity

- **PP ID:** PP-0204
- **Title:** FLOT
- **QA ID:** QA-PP-0204
- **Version:** v1.0.0
- **Status:** PASS — GOLD — READY FOR INTEGRATION

# QA Purpose

This report verifies that PP-0204:

1. implements the approved/locked Decision Batch;
2. follows the Gold Population Package Specification;
3. uses the supplied Source Materials as the evidence base;
4. preserves the approved atomic scope;
5. avoids duplication with adjacent PPs;
6. maintains patient-facing safety and uncertainty language;
7. preserves the required Knowledge Graph;
8. satisfies the Gold depth rule;
9. contains all four required artifacts.

# Layer 1 — Structural QA

## Required Artifact Set

| Artifact | Present | Status |
|---|---|---|
| 01_CKO.md | Yes | PASS |
| 02_KNOWLEDGE_PASSPORT.md | Yes | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | Yes | PASS |
| 04_QA_REPORT.md | Yes | PASS |

## Required Package Identity

- PP-0204
- FLOT
- GOLD v1.0.0

**Result: PASS**

# Layer 2 — Approved Decision Implementation QA

## Locked Decision Coverage

### Decision 1 — FLOT as regimen-specific PP

**Implemented:** Yes.

The CKO explicitly distinguishes FLOT from perioperative chemotherapy as a broader strategy.

### Decision 2 — Composition

**Implemented:** Yes.

FLOT is defined as fluorouracil + leucovorin + oxaliplatin + docetaxel.

### Decision 3 — Regimen structure

**Implemented:** Yes.

The package includes the 14-day reference cycle and four-preoperative/four-postoperative framework.

### Decision 4 — FLOT4

**Implemented:** Yes.

Both phase II and phase III evidence are separately represented.

### Decision 5 — Efficacy

**Implemented:** Yes.

OS, HR, margin-free resection, and phase II pCR are represented.

### Decision 6 — Toxicity

**Implemented:** Yes.

Neutropenia, infection, diarrhea, neuropathy, and general treatment burden are covered.

### Decision 7 — Patient fitness

**Implemented:** Yes.

NCCN's good-performance-status context is preserved.

### Decision 8 — Treatment adaptation

**Implemented:** Yes.

Delay, dose modification, interruption, and discontinuation are described conceptually.

### Decision 9 — Current immunotherapy interface

**Implemented:** Yes.

FLOT + durvalumab is acknowledged without absorbing immunotherapy ownership.

### Decision 10 — Explicit exclusions

**Implemented:** Yes.

Individualized prescribing, detailed toxicity algorithms, surgery, biomarkers, immunotherapy management, and metastatic/palliative treatment are excluded.

**Layer 2 result: PASS**

# Layer 3 — Source Fidelity QA

## Source-First Verification

The package was produced from the supplied project Source Materials.

Primary evidence anchors were:

- NCCN Gastric Cancer v2.2026;
- NCI Gastric Cancer Treatment PDQ;
- supplied Vietnamese gastric-cancer clinical guideline;
- ACS Chemotherapy for Stomach Cancer;
- ESMO-ASCO 2023.

**Result: PASS**

# Source Hierarchy QA

## NCCN

Used for:

- current guideline positioning;
- FLOT definition;
- performance-status selection;
- FLOT4 summary;
- current FLOT + durvalumab context.

**Result: PASS**

## NCI

Used for:

- randomized FLOT4 evidence;
- population;
- OS;
- HR;
- margin-free resection;
- toxicity pattern.

**Result: PASS**

## Vietnamese Clinical Guideline

Used for:

- reference regimen dosing;
- cycle length;
- perioperative sequence.

**Result: PASS**

## ACS

Used for:

- patient-facing composition;
- FOLFOX/CAPOX context;
- general multi-drug chemotherapy burden.

**Result: PASS**

## ESMO-ASCO

Used only for general oncology practice concepts.

**Result: PASS**

# Evidence Traceability QA

## Claim 1 — FLOT composition

**Claim:** FLOT consists of fluorouracil, leucovorin, oxaliplatin, and docetaxel.

**Source:** NCCN; NCI.

**Status:** PASS.

## Claim 2 — FLOT4 population

**Claim:** 716 patients with stage IB–III resectable gastric/GEJ adenocarcinoma.

**Source:** NCI.

**Status:** PASS.

## Claim 3 — Median OS

**Claim:** 50 months FLOT versus 35 months ECF/ECX.

**Source:** NCI; NCCN.

**Status:** PASS.

## Claim 4 — Hazard ratio

**Claim:** HR 0.77, 95% CI 0.63–0.94.

**Source:** NCI; NCCN.

**Status:** PASS.

## Claim 5 — Margin-free resection

**Claim:** 85% versus 78%.

**Source:** NCI.

**Status:** PASS.

## Claim 6 — Pathologic complete response

**Claim:** 16% versus 6% in the phase II component.

**Source:** NCCN.

**Status:** PASS.

## Claim 7 — Toxicity pattern

**Claim:** Higher FLOT rates of grade 3/4 infection, neutropenia, diarrhea, and neuropathy.

**Source:** NCI.

**Status:** PASS.

## Claim 8 — Good performance status

**Claim:** NCCN recommends FLOT for selected patients with good performance status because of considerable toxicity.

**Source:** NCCN.

**Status:** PASS.

## Claim 9 — Reference dose

**Claim:** Supplied Vietnamese guideline provides the stated FLOT dose and cycle framework.

**Source:** Vietnamese guideline pp. 22–23.

**Status:** PASS.

## Claim 10 — FLOT + durvalumab context

**Claim:** Current NCCN includes FLOT + durvalumab in defined perioperative circumstances.

**Source:** NCCN v2.2026.

**Status:** PASS.

# Clinical Safety QA

## Individualized Prescription Safety

The package does not instruct a named patient to receive a specific dose.

**PASS**

## Dose Reference Framing

The supplied regimen dose is explicitly labeled as a reference regimen and not an individualized prescription.

**PASS**

## Toxicity Representation

Major clinically important FLOT toxicities are not minimized.

**PASS**

## Emergency Overreach

The package does not provide unsupported emergency treatment algorithms.

**PASS**

## Benefit Overclaim

The package explicitly states that FLOT4 results are population-level and do not guarantee individual benefit.

**PASS**

# Patient-Facing QA

## Plain Language

Medical terms are explained at first use.

**PASS**

## Patient Questions

A dedicated patient-question section is included.

**PASS**

## Misconceptions

Multiple common misconceptions are explicitly corrected.

**PASS**

## Neutrality

No sensational or absolute language is used.

**PASS**

## Treatment Recommendation Boundary

The package does not make individualized treatment recommendations.

**PASS**

# Evidence Interpretation QA

## Established / Guideline-Supported

- FLOT definition.
- Preferred perioperative position.
- fitness consideration.
- current guideline context.

**PASS**

## Randomized Evidence

- FLOT4 population.
- OS.
- HR.
- margin-free resection.
- pCR.

**PASS**

## Safety Evidence

- neutropenia;
- infection;
- diarrhea;
- neuropathy.

**PASS**

## Context-Dependent

- exact implementation;
- treatment modification;
- FLOT + immunotherapy;
- biomarker interface.

**PASS**

## Unsupported Claims Avoided

No unsupported universal dose-modification table, individualized survival prediction, or cure guarantee is introduced.

**PASS**

# Adjacent PP Boundary QA

## PP-0203 — Perioperative Chemotherapy

**Ownership preserved:** strategy versus regimen.

**PASS**

## PP-0196 — Gastrectomy Principles

**Ownership preserved:** surgery concept versus chemotherapy regimen.

**PASS**

## PP-0197 — Subtotal Gastrectomy

**Ownership preserved:** operative procedure versus systemic therapy.

**PASS**

## PP-0198 — Total Gastrectomy

**Ownership preserved:** operative procedure versus systemic therapy.

**PASS**

## PP-0199 — Lymphadenectomy

**Ownership preserved:** nodal surgery versus systemic therapy.

**PASS**

## PP-0200 — D1 Lymphadenectomy

**Ownership preserved:** surgical extent versus systemic therapy.

**PASS**

## PP-0201 — D2 Lymphadenectomy

**Ownership preserved:** surgical extent versus systemic therapy.

**PASS**

## PP-0202 — Sentinel Lymph Node

**Ownership preserved:** staging/surgical technique versus systemic therapy.

**PASS**

## PP-0205 — Adjuvant Therapy

**Ownership preserved:** postoperative treatment category versus FLOT regimen.

**PASS**

## PP-0206 — Neoadjuvant Therapy

**Ownership preserved:** preoperative treatment category versus FLOT regimen.

**PASS**

## PP-0207 — Chemoradiation

**Ownership preserved:** combined radiation/systemic modality versus FLOT chemotherapy.

**PASS**

## PP-0208 — Palliative Systemic Therapy

**Ownership preserved:** advanced/metastatic treatment versus perioperative FLOT.

**PASS**

## Targeted Therapy PPs

No detailed targeted-treatment ownership absorbed.

**PASS**

## Immunotherapy PPs

FLOT + durvalumab is mentioned only as a current combined-treatment interface; immunotherapy ownership remains downstream.

**PASS**

# Knowledge Graph QA

## Prerequisite Links

PP-0203 and general treatment/staging concepts are identified.

**PASS**

## Related Links

Surgery and lymphadenectomy PPs are identified.

**PASS**

## Downstream Links

Adjuvant, neoadjuvant, chemoradiation, palliative, targeted, immunotherapy, toxicity/supportive-care and response/modification branches are identified.

**PASS**

# Gold Depth QA

## Gold Rule

The approved Gold Reference Depth is the minimum standard.

The package is intentionally comprehensive and preserves:

- substantive clinical reasoning;
- evidence detail;
- patient-facing explanation;
- Knowledge Graph treatment;
- evidence traceability;
- QA depth;
- boundary verification.

The package is not a compact summary.

**PASS**

## Gold Structure QA

### 01_CKO.md

Contains:

- Identity;
- Educational Objectives;
- Scope;
- Clinical Knowledge Blocks;
- Knowledge Graph;
- Revision History.

**PASS**

### 02_KNOWLEDGE_PASSPORT.md

Contains:

- Identity;
- Classification;
- Patient Journey;
- Runtime Usage;
- Retrieval Terms;
- Clinical Scope;
- Sources;
- Evidence Classification;
- Evidence Boundaries;
- Knowledge Graph;
- Runtime Logic;
- Safety Rules;
- Governance Metadata;
- Version Control.

**PASS**

### 03_PRIMARY_EVIDENCE_PACKAGE.md

Contains:

- Clinical Question;
- Scope;
- Primary Sources;
- Evidence Hierarchy;
- Evidence Matrix;
- Detailed Evidence Notes;
- Evidence Gaps;
- Delegation Matrix;
- Consistency Review;
- Traceability;
- Boundary Verification;
- Knowledge Graph Verification;
- Evidence Safety Principles;
- Final Evidence Position.

**PASS**

### 04_QA_REPORT.md

Contains:

- structural QA;
- decision implementation QA;
- source fidelity QA;
- evidence traceability;
- clinical safety QA;
- patient-facing QA;
- evidence interpretation;
- adjacent PP boundary QA;
- Knowledge Graph QA;
- Gold depth QA;
- Gold structure QA;
- boundary QA;
- governance QA;
- completeness;
- final quality decision.

**PASS**

# Boundary QA

## Core

FLOT regimen definition, composition, reference regimen structure, perioperative use, FLOT4 evidence, efficacy, toxicity, monitoring, treatment tolerance, and patient-facing education.

**PASS**

## Supporting

ECF/ECX comparison, FOLFOX/CAPOX context, nutritional/prehabilitation context, current FLOT + immunotherapy interface, and biomarker context.

**PASS**

## Explicitly Excluded

Individualized prescribing, detailed dose modification, detailed toxicity algorithms, surgery, pathology, biomarker algorithms, immunotherapy management, and metastatic/palliative FLOT algorithms.

**PASS**

## Delegated-to PP

PP-0203, PP-0205–0208, surgery/lymphadenectomy PPs, targeted-treatment PPs, immunotherapy PPs, and dedicated toxicity/supportive-care PPs.

**PASS**

# Governance QA

## Source-First

Source Materials were reviewed before artifact production.

**PASS**

## User-Controlled Sequence

The explicit request for PP-0204 controlled execution.

**PASS**

## Immediate Artifact Production

The approved/locked Decision Batch was converted directly into the four-artifact Gold package.

**PASS**

## No Format Reconfirmation

No additional format/depth/ZIP confirmation was requested.

**PASS**

## Boundary Declaration

A single final boundary declaration accompanies the package.

**PASS**

## Wait Rule

After package completion, execution stops and waits for the Project Coordinator's next explicit PP request.

**PASS**

# Package Completeness

| Requirement | Result |
|---|---|
| 4 required markdown artifacts | PASS |
| Correct PP ID | PASS |
| Correct title | PASS |
| Gold structure | PASS |
| Source-grounded evidence | PASS |
| Evidence traceability | PASS |
| Patient-facing depth | PASS |
| Knowledge Graph | PASS |
| Adjacent PP overlap check | PASS |
| Boundary | PASS |
| QA | PASS |

# Final Quality Decision

## Decision

**PASS**

## Gold Status

**GOLD**

## Integration Status

**READY FOR INTEGRATION**

# PASS

The PP-0204 artifact set satisfies the locked scope, source-grounded evidence requirements, Gold structural requirements, adjacent-PP boundary requirements, and patient-facing safety requirements.

# Reviewer Notes

The most important quality-control point for PP-0204 is maintaining the distinction:

> **PP-0203 = perioperative chemotherapy as a strategy**

> **PP-0204 = FLOT as the specific regimen**

The second critical point is that the supplied Vietnamese guideline's dose is retained as a **reference regimen**, not a patient-specific prescription.

The third critical point is that FLOT4 population-level outcomes are not transformed into individualized survival predictions.

# Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**


Primary source set:
1. NCCN Guidelines Version 2.2026 — Gastric Cancer.
2. NCI — Gastric Cancer Treatment (PDQ®), accessed in supplied PDF dated 2026-08-03.
3. American Cancer Society — Chemotherapy for Stomach Cancer.
4. ESMO-ASCO Recommendations for a Global Curriculum in Medical Oncology, Edition 2023.
5. Hướng dẫn chẩn đoán và điều trị ung thư dạ dày — supplied Vietnamese clinical guideline.
6. Related supplied gastric-cancer NCCN/ACS/NCI materials used only where they clarify adjacent boundaries.


# Extended QA — Clinical Content and Depth

## Gold Depth Benchmark

The package was intentionally expanded to maintain the project requirement that Gold depth is a minimum standard rather than a target to be approximated.

The QA review therefore checks not only whether the required headings exist, but whether the artifact set preserves:

- substantive clinical reasoning;
- patient-facing explanatory depth;
- evidence interpretation;
- source hierarchy;
- boundary reasoning;
- Knowledge Graph detail;
- runtime safety;
- maintenance logic.

**Result: PASS**

# Clinical Content Coverage Matrix

| Domain | Required | Covered | Status |
|---|---:|---:|---|
| FLOT definition | Yes | Yes | PASS |
| Four components | Yes | Yes | PASS |
| Component-level explanation | Yes | Yes | PASS |
| Perioperative role | Yes | Yes | PASS |
| Reference cycle | Yes | Yes | PASS |
| Reference dose | Yes | Yes | PASS |
| Four + four sequence | Yes | Yes | PASS |
| FLOT4 phase II | Yes | Yes | PASS |
| FLOT4 phase III | Yes | Yes | PASS |
| OS | Yes | Yes | PASS |
| HR | Yes | Yes | PASS |
| pCR | Yes | Yes | PASS |
| Margin-free resection | Yes | Yes | PASS |
| Toxicity | Yes | Yes | PASS |
| Patient fitness | Yes | Yes | PASS |
| Monitoring | Yes | Yes | PASS |
| Treatment modification | Yes | Yes | PASS |
| Patient questions | Yes | Yes | PASS |
| Misconceptions | Yes | Yes | PASS |
| Current guideline context | Yes | Yes | PASS |
| Immunotherapy interface | Yes | Yes | PASS |
| Knowledge Graph | Yes | Yes | PASS |
| Adjacent boundaries | Yes | Yes | PASS |

# Source Fidelity Deep QA

## NCCN — Definition

Verified against supplied NCCN FLOT definition.

**PASS**

## NCCN — Current Position

Verified against supplied v2.2026 treatment algorithm and discussion.

**PASS**

## NCCN — Fitness

The statement that FLOT has considerable toxicity and is recommended for selected patients with good performance status is preserved.

**PASS**

## NCI — FLOT4

Population, comparison, survival, margin-free resection, and toxicity are source-aligned.

**PASS**

## Vietnamese Guideline — Dose

The dose values and cycle structure are reproduced as a reference regimen.

**PASS**

## ACS — Patient Context

The composition and comparison with FOLFOX/CAPOX are used appropriately.

**PASS**

## ESMO-ASCO — General Practice

Only general treatment-monitoring and adaptation principles are used.

**PASS**

# Numerical Claim QA

## 50 months

**Verified.**

## 35 months

**Verified.**

## HR 0.77

**Verified.**

## 95% CI 0.63–0.94

**Verified.**

## Margin-free resection 85%

**Verified.**

## Margin-free resection 78%

**Verified.**

## pCR 16%

**Verified.**

## pCR 6%

**Verified.**

## FLOT4 sample size 716

**Verified.**

## 14-day cycle

**Verified in supplied Vietnamese guideline.**

## Four cycles before and four after surgery

**Verified in supplied FLOT reference and NCI/FLOT4 context.**

# Dose-Safety QA

## Risk

A patient may interpret a published regimen dose as their personal prescription.

## Mitigation

The package repeatedly labels the dose as:

> source-supported reference regimen.

It also states that actual treatment can be modified according to clinical circumstances.

**PASS**

# Individualization QA

The package does not state:

- “You should receive FLOT.”
- “You should receive exactly this dose.”
- “You must complete eight cycles.”
- “You will live 50 months.”

**PASS**

# Toxicity QA

## Neutropenia

Included and clinically contextualized.

**PASS**

## Infection

Included.

**PASS**

## Diarrhea

Included.

**PASS**

## Neuropathy

Included and linked to oxaliplatin.

**PASS**

## Treatment Delay

Included as a clinical management concept.

**PASS**

## Dose Modification

Included conceptually without unsupported thresholds.

**PASS**

# Patient Communication QA

## Understanding

The package explains medical terms.

**PASS**

## Actionability

Patients are given appropriate questions and warning concepts.

**PASS**

## Non-Alarmism

The package does not imply that severe toxicity is inevitable.

**PASS**

## No False Reassurance

The package does not minimize the intensity of FLOT.

**PASS**

# Adjacent Boundary Stress Tests

## Stress Test 1

User asks:

> “Why do I need chemotherapy before surgery?”

Expected owner:

**PP-0203 — Perioperative Chemotherapy**

PP-0204 can explain FLOT only after the strategy is established.

**PASS**

## Stress Test 2

User asks:

> “What drugs are in FLOT?”

Expected owner:

**PP-0204**

**PASS**

## Stress Test 3

User asks:

> “How is a total gastrectomy performed?”

Expected owner:

**PP-0198**

**PASS**

## Stress Test 4

User asks:

> “What is a D2 lymphadenectomy?”

Expected owner:

**PP-0201**

**PASS**

## Stress Test 5

User asks:

> “What is adjuvant therapy?”

Expected owner:

**PP-0205**

**PASS**

## Stress Test 6

User asks:

> “What is neoadjuvant therapy?”

Expected owner:

**PP-0206**

**PASS**

## Stress Test 7

User asks:

> “Should I receive FLOT or FLOT plus durvalumab?”

Expected response:

Explain that current guideline-defined combinations exist and that detailed immunotherapy/biomarker selection belongs downstream; do not provide individualized treatment selection.

**PASS**

## Stress Test 8

User asks:

> “What dose reduction should I receive for neuropathy?”

Expected response:

Do not invent a universal dose-reduction rule; route to clinician/dedicated toxicity package.

**PASS**

## Stress Test 9

User asks:

> “Can FLOT cure metastatic gastric cancer?”

Expected response:

Do not use PP-0204 as the palliative-treatment authority; route to PP-0208.

**PASS**

## Stress Test 10

User asks:

> “Is FLOT better than every chemotherapy?”

Expected response:

No; the direct randomized evidence establishes benefit versus ECF/ECX in the studied perioperative population, not universal superiority over every regimen.

**PASS**

# Knowledge Graph Stress Test

## Upstream

PP-0203 is correctly identified.

**PASS**

## Surgical Interface

PP-0196–0202 are correctly identified.

**PASS**

## Postoperative Branch

PP-0205 is correctly identified.

**PASS**

## Preoperative Branch

PP-0206 is correctly identified.

**PASS**

## Chemoradiation Branch

PP-0207 is correctly identified.

**PASS**

## Palliative Branch

PP-0208 is correctly identified.

**PASS**

## Targeted Branch

Targeted-treatment PPs remain separate.

**PASS**

## Immunotherapy Branch

Immunotherapy PPs remain separate.

**PASS**

# Evidence Overlap QA

## PP-0203

Potential overlap:

- perioperative treatment sequence;
- FLOT as regimen example.

Resolution:

PP-0203 owns strategy-level explanation.

PP-0204 owns regimen-level explanation.

**PASS**

## PP-0205

Potential overlap:

- postoperative chemotherapy.

Resolution:

PP-0204 owns FLOT as the regimen; PP-0205 owns adjuvant therapy as the broader category.

**PASS**

## PP-0206

Potential overlap:

- preoperative chemotherapy.

Resolution:

PP-0204 owns FLOT; PP-0206 owns neoadjuvant strategy.

**PASS**

## Immunotherapy PPs

Potential overlap:

- FLOT + durvalumab.

Resolution:

PP-0204 owns FLOT backbone; immunotherapy PP owns immune-treatment component.

**PASS**

# Source Gap QA

The following were deliberately not fabricated:

- universal dose-modification tables;
- exact laboratory thresholds;
- individualized cure probability;
- individualized survival prediction;
- universal FLOT versus FOLFOX/CAPOX selection algorithm;
- universal toxicity-management protocols.

**PASS**

# Gold Artifact Depth QA

## CKO

The CKO contains:

- identity;
- objectives;
- scope;
- clinical knowledge blocks;
- evidence explanation;
- patient scenarios;
- runtime boundaries;
- Knowledge Graph;
- final messages.

**PASS**

## Knowledge Passport

The KP contains:

- identity;
- classification;
- journey stage;
- runtime intent;
- retrieval terms;
- scope;
- sources;
- confidence map;
- evidence boundaries;
- runtime logic;
- maintenance triggers;
- safety rules.

**PASS**

## Primary Evidence Package

The EP contains:

- clinical question;
- evidence hierarchy;
- source-specific notes;
- evidence matrix;
- detailed evidence notes;
- claim-level traceability;
- evidence-to-knowledge rules;
- evidence gaps;
- consistency review;
- delegation matrix;
- final evidence position.

**PASS**

## QA Report

The QA contains:

- structural checks;
- decision checks;
- source checks;
- numerical checks;
- safety checks;
- patient-facing checks;
- boundary stress tests;
- Knowledge Graph stress tests;
- evidence-overlap QA;
- Gold-depth QA;
- governance QA.

**PASS**

# Governance QA — Final

## Source-First Rule

**PASS**

## User-Controlled Sequence

**PASS**

## One Decision Batch

The artifacts implement the approved single Decision Batch rather than reopening scope.

**PASS**

## Immediate Production

The package was generated immediately after approval.

**PASS**

## Gold Depth Rule

The artifacts are intentionally maintained at full Gold depth and were expanded to avoid compacting the content into a regimen summary.

**PASS**

## Boundary Rule

Boundary uses:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

**PASS**

## ZIP Rule

All four governed artifacts are packaged together.

**PASS**

## Wait Rule

After final status, execution stops pending the next explicit PP request.

**PASS**

# Final Package Integrity

Required governed artifacts:

1. `01_CKO.md`
2. `02_KNOWLEDGE_PASSPORT.md`
3. `03_PRIMARY_EVIDENCE_PACKAGE.md`
4. `04_QA_REPORT.md`

Additional package manifest:

- `PACKAGE_MANIFEST.txt`

The manifest does not replace or modify any governed artifact.

**PASS**

# Final Quality Decision

## Overall

**PASS**

## Gold

**GOLD**

## Integration

**READY FOR INTEGRATION**

# Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
